Premium Phosphosite-Specific 7TM Antibodies
Novel Tools for Your GPCR Research
Select Your Country of Delivery below

Immuno-Grade Neurokinin Receptor 1 Antibodies

Close filters
No results were found for the filter!
Citations
Immunohistochemical identification of Tachykinin Receptor 1 in pancreatic carcinoma
NK1 (IHC-grade), Tachykinin Receptor 1 Receptor...
The NK1 antibody is directed against the distal end of the carboxyl-terminal tail of human Tachykinin Receptor 1 (also called Substance P Receptor). It detects selectively the canonical full-length NK1 Tachykinin Receptor. It can be used...
$ 375.00 *
Details

The tachykinin receptor 1 (NK1, neurokinin receptor 1) is the specific receptor for substance P and with lower affinity for other tachykinin peptides such as neurokinin A (NKA) and neurokinin B (NKB). NK1 is widely distributed in both the central nervous system and peripheral tissues including the substantia nigra, the hypothalamus, the central amygdala, the frontal cortex as well as the gastrointestinal tract. NK1 is the pharmacological target for aprepitant (MK0869; Emend), which is used for post operative/chemotherapy-induced nausea and vomiting. NK1 receptors are also frequently expressed in glioblastomas and breast and pancreatic carcinomas.

The tachykinin receptor 1 (NK1, neurokinin receptor 1) is the specific receptor for substance P and with lower affinity for other tachykinin peptides such as neurokinin A (NKA) and neurokinin B... read more »
Close window
Immuno-Grade Neurokinin Receptor 1 Antibodies

The tachykinin receptor 1 (NK1, neurokinin receptor 1) is the specific receptor for substance P and with lower affinity for other tachykinin peptides such as neurokinin A (NKA) and neurokinin B (NKB). NK1 is widely distributed in both the central nervous system and peripheral tissues including the substantia nigra, the hypothalamus, the central amygdala, the frontal cortex as well as the gastrointestinal tract. NK1 is the pharmacological target for aprepitant (MK0869; Emend), which is used for post operative/chemotherapy-induced nausea and vomiting. NK1 receptors are also frequently expressed in glioblastomas and breast and pancreatic carcinomas.

Recently viewed